Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DCSZ11 |
Synonyms | |
Therapy Description |
DCSZ11 is a monoclonal antibody that targets an epitope of C1QR1 (CD93) and prevents the interaction of C1Q1R and its ligand IGFBP7, potentially resulting in decreased tumor cell proliferation and increased immune cell infiltration in the tumor microenvironment (NCI Drug DIctionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DCSZ11 | DCSZ-11|DCSZ 11 | DCSZ11 is a monoclonal antibody that targets an epitope of C1QR1 (CD93) and prevents the interaction of C1Q1R and its ligand IGFBP7, potentially resulting in decreased tumor cell proliferation and increased immune cell infiltration in the tumor microenvironment (NCI Drug DIctionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05785754 | Phase I | DCSZ11 | DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |